瘤学家对患者在癌症治疗期间管理先前存在的慢性并发症的感知信心和态度
Dudith Pierre-Victor1, Iman K Martin2, Brenda Adjei3
1ConcertAI, LLC.
Journal of the National Medical Association
|May 29, 2023
概括
瘤学家在癌症治疗期间对管理先前存在的慢性疾病 (PECC) 感到自信,但当这些疾病以前由其他专家管理时,信心会下降. 他们支持共同管理,以改善患者护理.
科学领域:
- 在瘤学瘤学.
- 内部医学 内部医学
- 医疗保健管理的管理
背景情况:
- 对瘤学家来说,与积极的癌症治疗 (ACT) 一起管理先前存在的慢性疾病 (PECC) 是一个挑战.
- 确保为患有并发症的癌症患者提供协调和全面的护理对于最佳结果至关重要.
研究的目的:
- 评估实践瘤学家在ACT期间对PECC管理的信心和态度.
- 探索专业和先前管理如何影响瘤学家对处理PECC的信心.
主要方法:
- 在国家癌症研究所社区瘤学研究计划 (NCORP) 中的瘤学家进行了在线调查.
- 该调查评估了对管理PECC和与非瘤医疗提供者共同管理的感知信心和态度.
- 基于专业和实践变量,使用统计分析,包括皮尔森千平方测试,以确定信心和态度的差异.
主要成果:
- 大多数瘤学家 (68.3%) 感到有信心在标准护理中管理PECC.
- 当PECC之前由初级保健医生 (46.6%) 或非瘤学子专家 (19.7%) 管理时,信心显著下降.
- 大多数瘤学家 (63.7%) 同意,与非瘤学提供者共同管理导致最佳的癌症和非癌症护理.
结论:
- 虽然瘤学家通常对在ACT期间管理PECC充满信心,但对于其他专家管理的疾病,他们的信心会下降.
- 瘤学家对联合管理表达了积极的态度,强调其对协调患者护理的重要性.
- 研究结果表明,需要加强瘤学家和非瘤学家之间的合作,以改善对PECC癌症患者的护理.
更多相关视频
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.9K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.6K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Tumor Immunotherapy
577
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
577
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
COPD: Management Using Bronchodilators and Corticosteroids
256
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
256
